Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Recommendation of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $11.40.

A number of analysts have recently issued reports on ATNM shares. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday. B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. Maxim Group cut their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th.

Check Out Our Latest Stock Report on ATNM

Actinium Pharmaceuticals Stock Down 5.7 %

Shares of ATNM opened at $1.42 on Tuesday. The business has a fifty day moving average price of $1.79. Actinium Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $10.24. The stock has a market cap of $44.15 million, a price-to-earnings ratio of -1.01 and a beta of 0.14.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the last quarter. Virtu Financial LLC raised its stake in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Rhumbline Advisers grew its stake in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals in the second quarter valued at about $142,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Free Report

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Featured Stories